Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Regulation of inducible BALT formation and contribution to immunity and pathology

Abstract

Inducible bronchus-associated lymphoid tissue (iBALT) is an organized tertiary lymphoid structure that is not pre-programmed but develops in response to infection or under chronic inflammatory conditions. Emerging research has shown that iBALT provides a niche for T-cell priming and B-cell education to assist in the clearance of infectious agents, highlighting the prospect that iBALT may be engineered and harnessed to enhance protective immunity against respiratory pathogens. Although iBALT formation is associated with several canonical factors of secondary lymphoid organogenesis such as lymphotoxin-α and the homeostatic chemokines, CXCL13, CCL19, and CCL21, these cytokines are not mandatory for its formation, even though they influence its organization and function. Similarly, lymphoid tissue-inducer cells are not a requisite of iBALT formation. In contrast, dendritic cells are emerging as pivotal players required to form and sustain the presence of iBALT. Regulatory T cells appear to be able to attenuate the development of iBALT, although the underlying mechanisms remain ill-defined. In this review, we discuss facets unique to iBALT induction, the cellular subsets, and molecular cues that govern this process, and the contribution of this ectopic structure toward the generation of immune responses in the pulmonary compartment.

Introduction

Bronchus-associated lymphoid tissue (BALT) was first identified and described as a constitutive structure in the lungs of rabbits more than 30 years ago.1 BALT was initially described as follicular aggregations primarily composed of lymphocytes located, in general, along the bifurcations of the upper bronchi and between an artery and a bronchus.2 It is now recognized that BALT is an organized structure with T- and B-cell areas, high endothelial venules (HEVs) in the T-cell zone, and an overlying lymphoepithelium containing cells similar to microfold cells of Peyer's patches (PPs).3, 4 Follicular dendritic cells (FDCs) in the BALT present antigen to B cells,5 as well as providing costimulatory signals that enhance B-cell activation and proliferation in the germinal centers (GCs).6, 7 The majority of cells within BALT are IgMloIgDhi-expressing B cells, although immunoglobulin (Ig)G1-, IgA,- and even IgE-positive plasma cells may also be observed depending on the nature of the microbe and/or antigen to which the cells are responding.8, 9, 10, 11

BALT is considered to be part of the integrated mucosal system, which includes the gut-associated lymphoid tissue and nasal-associated lymphoid tissue (NALT) among others. It is regarded as a tertiary lymphoid tissue for unlike canonical secondary lymphoid organs (SLOs), BALT development is not pre-programmed, commences postnatally, and occurs anatomically at non-lymphoid locations. BALT formation can be induced under a range of disease states characterized by chronic inflammation, infection, or autoimmunity,12 and these structures are now preferentially termed inducible BALT (iBALT). They are distinct from the classical BALT in that they do not always possess an overlying epithelium, are not always found in association with an airway, and may form in the lung parenchyma.

The prevalence of BALT differs between species, being common in rabbits and rats and largely absent in healthy humans and mice.13, 14 Emerging data now evidence a role of infectious agents suggesting that, like isolated lymphoid follicles (ILFs) in the gut,15 iBALT may develop in response to microbial exposure. However, it is noteworthy that BALT has been described in germ-free rats1 and mice.9

Disease States

Tertiary lymphoid organs (TLOs) are often noted in patients with chronic inflammatory diseases. These ectopic structures are characterized by distinct T- and B-cell areas supported by specialized vascular systems that arise in atypical regions.16, 17 TLOs have been shown to form in Sjogren's syndrome in both the lungs and salivary glands,18, 19 in the lungs of subjects with idiopathic pulmonary fibrosis,20 and in the joints and lungs of individuals with rheumatoid arthritis (RA).19, 21, 22, 23 Indeed, in the cohort of RA patients studied by Sato et al.,23 BALT was observed in all eight subjects.

iBALT is frequently observed in lung tissue obtained from patients with asthma (another chronic inflammatory disease) and is evident in mouse models of experimental asthma. In a detailed clinical analysis, Elliot et al.24 revealed that cases with asthma tended to have larger and greater numbers of these aggregates as compared with non-asthma cases, regardless of asthma severity. The overexpression of interleukin (IL)-5 in the mouse has been reported to promote iBALT, although whether this response is mediated through a direct effect on B cells remains to be determined.25 In a mouse model of allergic pulmonary inflammation, antigen-specific IgE-secreting plasma cells were shown to reside adjacent to the GCs in BALT.11 Clearly, reducing IgE synthesis is an attractive strategy for the treatment of asthma and other diseases in which IgE-mediated degranulation of mast cells and basophils contributes to disease pathogenesis.

Non-classical BALT lacking contact with the epithelium has also been observed in 84% of smokers and 14% of non-smokers.26 Consistent with this, lymphoid follicles have been detected in the airways and parenchyma of mice exposed to cigarette smoke.27 These organized structures have also been noted in patients with chronic obstructive pulmonary disease (COPD), of which smoking is the leading cause.28 Respiratory viral infections, which have been implicated as a major risk factor for exacerbations of COPD, may also be causative agents of iBALT formation. Indeed, iBALT form within 10 days in mice following inoculation with influenza virus, even in the absence of the key cytokine lymphotoxin-α (LT-α).29 Administration of a replication-deficient strain of Vaccinia virus could also promote iBALT formation,30 suggesting that acute inflammation downstream of pattern recognition receptor (PRR) activation may be sufficient to initiate organogenesis. In this vein, Luhrmann et al.31 have demonstrated that rats repeatedly exposed to a toll-like receptor (TLR)2/6 ligand (MALP-2), developed larger BALT as compared with mice treated with control diluent alone. We and others have shown that a single exposure to the TLR4 ligand, lipopolysaccharide, is sufficient to drive the process of lymphoid neogenesis in the lungs of rats and mice32 (S.Y. Foo, P.S. Foster and S. Phipps, unpublished data). A similar program appears to operate in the gut, where hundreds of ILFs are only induced after birth in response to the local commensal flora.33 Notably, the size and number of ILFs was observed to correlate with the size of the gut flora.15 Collectively, these findings suggest that iBALT (like other TLOs) develops under a number of pathological states and that the activation of PRR by infectious and non-infectious stimuli may be a common underlying cause of iBALT neogenesis.

LTi Cells and iBALT Formation

Many of the molecular and cellular requirements of SLO formation are also apparent during organogenesis of TLO. However, it is now emerging that a number of the cues that are indispensible for SLO formation are not absolutely necessary for iBALT formation. A greater understanding of distinct processes between SLO and iBALT formation will identify new targets for therapeutic intervention to either promote iBALT formation (e.g., for vaccine therapy) or resolution (e.g., to attenuate pathogenic autoimmune responses that may prosper in iBALT).

The classical model of lymphoid organogenesis for SLOs such as the lymph nodes (LNs) and PPs involves the interaction of a unique subset of hematopoietic cells, known as lymphoid tissue-inducer (LTi) cells, with local stromal organizer cells. This communication results in the upregulation of adhesion molecules such as vascular cellular adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and mucosal addressin cell adhesion molecule-1 (MAdCAM-1), as well as the secretion of a panel of lymphocyte-homing chemokines and pleiotropic cytokines.

CD3CD4+CD45+ LTi cells are derived from fetal liver progenitors34 and are widely regarded as the earliest cell type to colonize the lymphoid anlagen of SLOs. It was recently determined that LTi cell differentiation is dependent upon at least two transcription factors, Id2 and ROR-γt. Hence, LTi cells are absent in mice lacking Id2 or ROR-γt, and this affects the development of peripheral LN, PPs, ILFs, and NALT, while splenic architecture is normal.35, 36, 37 LTi cells have been shown to accumulate in developing NALT and the adoptive transfer of these cells to Id2-deficient mice reconstituted the formation of NALT.38 The formation of other SLOs absent from Id2-deficient mice was not achieved using this protocol, as the transfer of cells occurred after birth, and therefore after the developmental window during which LN and PP formation is initiated. Thus, Id2-regulated LTi cells are the common ancestor (or inducer) cells for the organogenesis of NALT and PPs.

In contrast to SLO, limited evidence is available on the requirement for LTi cells in TLO formation. However, the observation that ectopic structures can form in the thyroid glands of Id2-deficient mice39 suggests that other cellular subsets may be able to compensate for the instructive signals normally delivered by LTi cells.40 These include mature CD3+CD4+ T lymphocytes, B cells expressing LTα1β2,41 and T cells expressing LIGHT (another ligand of LT-β receptor (LT-βR)).42 To date, iBALT formation has not been shown to require the recruitment of LTi cells. As such, the cells that constitute the anlagen and seed the development of the iBALT appear distinct from those that generate SLOs and ILFs, and their identity remains unknown at this time (Figure 1). The identification of the inducer population(s) and/or essential molecular pathway in iBALT formation could allow the selective induction or resolution of this ectopic structure as required.

Figure 1
figure1

Under conditions of infection/inflammation, various antigens may stimulate PRRs (such as TLRs) on bronchoeptithelial cells or DCs. The early analgen that eventually gives rise to an iBALT depends on complex interactions between a number of cell types including activated DCs and stromal cells. Through the release of a host of chemokines, cytokines and the expresion of a unique combination of adhesion molecules on HEVs, B and T cells are recruited to the site and often organized into distinct zones. FDCs are found within the B-cell region where they present antigen and co-stimulatory signals to the B cells. It has been established that DCs are critical for the maintenance of iBALT structures. Tregs in the draining mediastinal LNs are able to attenuate iBALT formation, but the mechnism(s) by which they exert their suppressive effects from this remote location remains unknown. It is possible that Tregs my inhibit the activation/proliferation/exit of an as yet unidentified population of cells in the dLNs that then migrate to the lungs to initiate iBALT formation.

PowerPoint slide

TNF Family Members and Homeostatic Chemokines

Selected members of the tumor necrosis factor (TNF) family have been shown to be essential for the formation and organization of SLOs—namely, LT-α/β, LIGHT, as well as TNF-α itself.40, 44, 45 The LTα1β2 heterotrimer is expressed on the surface of LTi cells and upon engagement of the cognate receptor LT-βR on stromal cells, triggers the production of the homeostatic chemokines CXCL13, CXCL12, CCL19, and CCL21. The resultant accumulation of B and T lymphocytes produces a second “wave” and rich supply of LTα1β2, which acts in a positive feedback loop to further enhance chemokine expression and cell recruitment.46, 47 In support of LT activation of stromal cells, HEVs in LT-deficient mice lack the expression of key factors such as peripheral node addressin (PNAd), GlyCAM-1, and the enzyme HEC-6ST, which is required for the luminal expression of PNAd.48

Lymphocytes enter the BALT after first tethering to adhesion molecules, such as PNAd and VCAM-1, but not MAdCAM-1, expressed by HEVs.49, 50 Notably, the strong luminal expression of VCAM-1 in BALT HEVs does not occur in SLOs. The L-selectin-PNAd pathway and LFA-1 is crucial for lymphocyte homing, whereas α4 integrin and VCAM-1 facilitate the recruitment of memory T cells to BALT.49 Taken together, these findings suggest that the HEVs in iBALT possess a unique pattern of adhesion molecule expression and therefore the entry requirements for lymphocytes to this compartment may be distinct from LNs and other SLOs.

One of the main challenges in the field of lymphoid neogenesis is to elucidate the carefully choreographed processes that direct cell recruitment and/or proliferation of many different cell types to generate a highly organized structure that is not pre-programmed. On the basis of a number of clinical studies documenting different lung pathologies, and animal work in factor-deficient and transgenic mice, it appears that at least three common events may initiate TLO formation: (i) activation of innate PRR, (ii) inflammatory cytokine (such as TNF-α or LT) and lymphoid chemokine production by hematopoietic or stromal cells, and (iii) activation/maturation of antigen-presenting cells and HEV development. For example, the size and complexity of TLOs in patients with autoimmune diseases has been shown to correlate with the expression of homeostatic chemokines and cytokines, in particular LT-α/β,19 CXCL13, and CCL21.51, 52 LT-α is critical to the development and organization of SLOs, as evidenced by the lack of all LNs, and PPs, and the presentation of abnormal splenic architecture in LT-α-deficient mice.53, 54 Loss of LT-βR signaling via the administration of a blocking LT-βR antibody in influenza-infected mice significantly decreased the number of iBALT structures and GC B cells.10 Despite this, the formation of iBALT has been observed in LT-α-deficient mice in response to influenza infection,29 although these structures were poorly organized and lacked FDCs and HEVs expressing PNAd. These defects were overcome when LT-α-deficient mice were reconstituted with wild-type bone marrow. Of note, LT-α-deficient mice were still able to mount a delayed immune response and significantly, this was observed to be less pathological. This elegant study suggests that precise structural organization of iBALT is not absolutely necessary for its functionality and that iBALT may assist in the development and regulation of optimal protective immunity at the local tissue site.

The transgenic overexpression of TNF-α in the lung can result in the development of lymphoid organs both around the airways and in the parenchyma,55 consistent with the increased expression of TNF-α in patients with Sjogren's syndrome, COPD, and RA. The overexpression of IL-6 together with its cognate receptor IL-6R also leads to iBALT formation.56 Although molecular insights into how either of these cytokines induce iBALT remain to be elucidated, both cytokines are potent inducers of homeostatic and inflammatory chemokines, which are likely to shape the early anlagen. CXCL13, for instance, is the archetypal B-cell chemoattractant and serves to regulate the compartmentalization of CXCR5+ B cells within the follicle.57 CXCL13 has a critical role in the development of all LNs, although its ectopic expression leads to lymphoid neogenesis.58 CXCL13 also recruits LTi cells and T follicular helper (TFH) cells,59 and is primarily produced by FDCs.41 Unexpectedly, however, Rangel-Moreno et al.43 have demonstrated that the absence of CXCL13 in the lung does not markedly affect iBALT formation in influenza-infected mice. These animals still developed well-organized follicles with segregated T- and B-cell areas, accompanied by HEVs and GCs, leading the authors to propose that other chemokines and/or as yet undiscovered ligands of CXCR5 may serve as a substitute for CXCL13.

Hyperplastic bronchial epithelial cells and T-cell zone fibroblastic reticular cells have been reported to express both the CCR7 ligands, CCL19 and CCL21.60, 61 Stromal cells were also identified as being the major source of CCL21 in NALT.62 In the iBALT of both humans and mice, CCL21 was frequently localized to endothelial cells and reticular cells that were either on the periphery of follicles or in the interfollicular areas.19, 29 Yet mice deficient in CCR7 spontaneously develop iBALT.9 Consistent with this, mice lacking both CCL19 and CCL21 (plt/plt mice) can develop iBALT with normal B-cell follicles. However, the T-cell areas are poorly organized and as a consequence both B and T-cell responses are impaired.43 Collectively, these findings highlight the importance of iBALT organization and productive T cell help to ensure optimal BALT functionality.

It has been established that the respiratory epithelium may participate in inflammation in several ways, either as target cells that alter their function in response to a variety of biological mediators, or as effector cells that directly contribute to inflammation. For instance, pulmonary epithelial cells express an array of innate PRR including TLR1-963 and secrete a plethora of cytokines, chemokines, and growth factors upon activation. These factors may initiate adaptive immunity through the maturation and migration of immature dendritic cells (DCs).64 It seems likely that the epithelium has a significant role in iBALT formation given its location and ability to influence the local DC network, which is emerging as integral component to iBALT formation and persistence (see below), yet this has yet to be specifically examined.

Age Dependency

It is notable that BALT has been observed in the lungs of up to 50% of healthy infants and young children, suggesting a predisposition in early life.65, 66 Gould and Isaacson67 recorded the presence of BALT in human fetal and infant lungs and concluded that its appearance is probably dependent on antigenic stimulus, in agreement with the findings of others who had established an association between the amount of antigenic stimulation and BALT formation in humans.68, 69

As the development of most SLOs is pre-programmed and occurs before birth, it has been hypothesized that TLOs would be more readily induced during a defined developmental window soon after birth, when the SLO are functionally immature.16 In support of this, the adoptive transfer of neonatal LN cells to the skin of neonatal mice was found to induce lymphoid structures displaying clear segregation of B- and T-cell areas, FDCs, and HEVs.70 By contrast, the administration of these cells to adult mice only generated disorganized aggregates of lymphocytes lacking FDCs. Remarkably, the organization of these ectopic structures was enhanced after the administration of an agonistic anti-CD40 antibody to mimic immune activation. This highlights the distinctive ability of neonates to develop more organized ectopic structures when compared with adult mice, in which the structural organization process is potentially antigen dependent. In a study designed to investigate the effect of age on allergic senitization, we observed that mice treated with lipopolysaccharide in the first week of life develop more iBALT than mice exposed at 4 weeks of age71 (S.Y. Foo, P.S. Foster and S. Phipps, unpublished data). Other studies reported differences in the leukocyte influx into the lung interstitium between rats of different ages after the intratracheal application of MALP-2.72, 73 Taken together with clinical observations, these findings caution against generalizations of the immune responses between different age groups and suggest that susceptibility to develop iBALT is heightened in early life. However, the molecular pathways that underpin this phenomenon remain undefined.

Dendritic Cells Contribute to iBALT Formation and Persistence

CD11c+ conventional DCs (cDCs) and CD21+ FDCs are regular features of iBALT, with the former often interspersed within the T- and B-cell area and the latter usually found within B-cell follicles.19, 29, 74 Although a large body of literature exists on the antigen presentation abilities of DCs,75 less is known in regard to their function in orchestrating TLO development and organization. However, emerging evidence suggests that DCs are likely to be important organizers of iBALT formation as they are among the earliest cells to colonize the anlagen. In addition, two studies published in 2009 have demonstrated that DCs are necessary for the maintenance of iBALT in response to virus infection.10, 30 Diptheria toxin-induced deletion of DCs after viral clearance led to a gradual decline in the number and size of iBALT structures. Strikingly, the lack of DCs coincided with the disappearance of virus-specific plasma cells and led to decreased IgA titers in the lung and virus-specific antibody titers in serum. Previous studies have implicated DCs as a potent source of inflammatory and homeostatic chemokines,76 and this was supported by GeurtsvanKessel et al. who demonstrated that the expression of key factors, such as CXCL12, CXCL13, CCL19, and CCL21, increased over time in lung DCs sorted from infected mice. Thus, in addition to presenting antigenic and costimulatory signals, DCs may promote the entrance and survival of lymphocytes within the iBALT. More recently, plasmacytoid DCs were found to accumulate in the lymphoid follicles of COPD patients.77 These were able to produce higher levels of TNF-α and IL-8 upon maturation as compared with plasmacytoid DCs from healthy subjects, but the role of these cells in iBALT formation and maintenance remains an open question.

Contribution of Regulatory T Cells to iBALT Formation

In light of the findings that DCs contribute to the formation and maintenance of iBALT, it is probable that alterations in regulatory T-cell (Treg) migration and function may affect iBALT formation. Originally identified as CD4+CD25+ cells that were crucial for the prevention of autoimmune diseases,78 forkhead box P3 (Foxp3) (+) Tregs have since been demonstrated to mediate their tolerogenic effects by suppressing effector T-cell responses, either directly or by modulating DC immunogenicity.79, 80, 81 These effects are primarily mediated through the release of inhibitory cytokines such as IL-10 and TGF-β or via contact-dependent mechanisms.82, 83

The first study to directly implicate a role of Tregs arose from an observation that CCR7-deficient mice spontaneously developed iBALT from 5 days of age even in the absence of an environmental insult.9 Although not functionally impaired, Tregs were unable to home to the draining LN of CCR7-deficient mice. Tregs are known to express the homing receptor CCR7 at high levels84 and may exert their suppressive activity in the draining LN, reiterating the potential importance of site-specific regulation.42 Of note, the adoptive transfer of wild-type Tregs to CCR7-deficient recipients attenuated iBALT formation. Thus, Tregs control the development of iBALT formation and mediate at least part of their suppressive effects in the LN compartment. Further evidence to support the interrelationship between LNs and BALT formation was illustrated following the transplantation of human fetal bronchial tissue to SCID mice; only when the peripheral LNs were cotransplanted did the mice develop BALT.85 Further studies will be required to delineate the origin of the cells targeted by Tregs and the molecular processes that mediate this inhibition. Curiously, immunophenotyping of bronchial biopsy specimen from human infants has shown that Foxp3+ CD4+ Tregs reside primarily within these follicles.86 Intriguingly, Foxp3+ CD4+ T cells may also differentiate into T follicular helper cells and proceed to participate in the induction of GCs and local IgA synthesis.87 Although this phenomenon is reportedly restricted in the context of SLOs to PPs and not spleen or LNs, it is tempting to speculate that a similar scenario may occur in the context of iBALT.

iBALT Contributes to Immunity

Elucidating the function(s) of TLOs, and in particular iBALT, remains an area of intense research. The initial concept of BALT being part of a common mucosal system88 was supported by the finding that gut-associated lymphoid tissue lymphocytes could populate the bronchial mucosa, and that the reverse was also true.89 Whether iBALT is beneficial or detrimental appears to be context dependent. Hogg et al.28 reported that the presence of lymphoid follicles resembling BALT correlates with disease severity in patients with COPD, whereas iBALT associates with local tissue pathology in the lungs of RA patients.19 In addition, BALT has been identified as a favorable site for pathogenic microorganisms during latency.90

In contrast, it has been proposed that iBALT may serve as an inducible lymphoid tissue for respiratory immune responses. To investigate this theory, Moyron-Quiroz et al.29 examined the adaptive response of mice lacking some or all peripheral lymphoid organs following inoculation with influenza virus. Remarkably, mice without SLOs were still able to generate a robust virus-specific cytotoxic T-cell response and virus-specific antibody production because of the presence of iBALT. Moreover, these mice survived higher doses of the virus as compared with their wild-type counterparts. In a similar study, the iBALT observed in influenza-infected mice lacking spleens, LNs, and PPs was found up to 90 days after infection.74 The authors proposed that iBALT was able to support the proliferation of virus-specific CD8+ T cells that then proceeded to clear a challenge infection. Further support of a protective role of iBALT has been provided in two recent studies that used microbial molecules to induce BALT before inoculation with a respiratory pathogen. Using mice deficient of peripheral lymphoid organs, Wiley et al.91 demonstrated that induction of iBALT formation with five doses of the non-infectious protein cage nanoparticle (PCN) over 12 days up till 3 days before infection accelerated the clearance of a variety of respiratory viruses. Importantly, PCN-treated mice displayed reduced lung damage after influenza virus infection as compared with control phosphate-buffered saline-treated mice. One significant caveat with these findings stems from separating the contribution of BALT per se vs. the adjuvant-inducing effects of the microbial ligands. It is noteworthy that increasing the length of time between PCN exposure and virus inoculation led to a dramatic fall off in efficacy. In another immunomodulatory study, iBALT was noted as early as 4 days after challenge in mice exposed to cholera toxin, a mutant form of the Escherichia coli heat-labile enterotoxin, or CpG oligodeoxynucleotides.92 Although the authors did not conduct further investigation into their role, they noted that the presence of iBALT correlated with improved survival when the mice were subsequently infected with a lethal dose of influenza virus.

More recently, Halle et al.30 have employed new technology to address the functionality of iBALT in an ex vivo culture system. Using two-photon microscopy, stable interactions between antigen-loaded DCs and antigen-specific T cells within iBALT were confirmed. These T cells were found to proliferate as well as those residing in the draining LN. As the antigen-specificity of the T cells differed from the antigen used to elicit the formation of the iBALT in this model, their findings support the idea of iBALT functioning as a general priming site for T cell responses. Taken together, these studies lend support to the concept that iBALT induction would be an advantageous element of future immunoprophylactic strategies charged with enhancing protective immunity against respiratory pathogens.

Concluding Remarks

Converging evidence suggests that the formation of iBALT can be initiated through the activation of innate PRR. As ectopic structures, the induction of iBALT has been shown to modulate adaptive immunity, either by contributing to the generation of beneficial humoral and cellular immune responses or exacerbating local tissue damage in autoimmune diseases. As iBALT can serve as an effective antigen presentation site, the development of novel adjuvants to promote its formation may enhance current vaccination strategies. Alternatively, resolution of iBALT may be desirable in the treatment of COPD and autoimmune diseases. To this end, a better understanding of the events that orchestrate iBALT formation will help to identify novel targets for the design of therapies to promote iBALT formation or removal. Several questions remain unanswered, including the nature of the cells that initiate the anlagen, the contribution of epithelial-derived mediators and local DC networks, the role of T follicular helper cells in iBALT formation and function, and the mechanisms by which Tregs control iBALT organogenesis. Ultimately, further investigation will be required to fully elucidate the immune signals that control the formation of iBALT. As more details emerge, understanding how to harness the inherent plasticity of these lymphoid structures will open up new avenues in the fields of adjuvant biology and vaccine development.

References

  1. 1

    Bienenstock, J., Johnston, N. & Perey, D.Y. Bronchial lymphoid tissue. I. Morphologic characteristics. Lab. Invest. 28, 686–692 (1973).

    CAS  PubMed  Google Scholar 

  2. 2

    Sminia, T., van der Brugge-Gamelkoorn, G.J. & Jeurissen, S.H. Structure and function of bronchus-associated lymphoid tissue (BALT). Crit. Rev. Immunol. 9, 119–150 (1989).

    CAS  PubMed  Google Scholar 

  3. 3

    Pankow, W. & von Wichert, P. M cell in the immune system of the lung. Respiration 54, 209–219 (1988).

    CAS  PubMed  Article  Google Scholar 

  4. 4

    Corr, S.C., Gahan, C.C. & Hill, C. M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol. Med. Microbiol. 52, 2–12 (2008).

    CAS  PubMed  Article  Google Scholar 

  5. 5

    Suzuki, K., Grigorova, I., Phan, T.G., Kelly, L.M. & Cyster, J.G. Visualizing B cell capture of cognate antigen from follicular dendritic cells. J. Exp. Med. 206, 1485–1493 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. 6

    van der Brugge-Gamelkoorn, G.J., van de Ende, M.B. & Sminia, T. Non-lymphoid cells of bronchus-associated lymphoid tissue of the rat in situ and in suspension. With special reference to interdigitating and follicular dendritic cells. Cell Tissue Res. 239, 177–182 (1985).

    CAS  PubMed  Article  Google Scholar 

  7. 7

    Kosco-Vilbois, M.H., Gray, D., Scheidegger, D. & Julius, M. Follicular dendritic cells help resting B cells to become effective antigen-presenting cells: induction of B7/BB1 and upregulation of major histocompatibility complex class II molecules. J. Exp. Med. 178, 2055–2066 (1993).

    CAS  PubMed  Article  Google Scholar 

  8. 8

    Milne, R.W., Bienenstodk, J. & Perey, D.Y. The influence of antigenic stimulation on the ontegeny of lymphoid aggregates and immunoglobulin-containing cells in mouse bronchial and intestinal mucosa. J. Reticuloendothel. Soc. 17, 361–369 (1975).

    CAS  PubMed  Google Scholar 

  9. 9

    Kocks, J.R., Davalos-Misslitz, A.C.M., Hintzen, G., Ohl, L. & Forster, R. Regulatory T cells interfere with the development of bronchus-associated lymphoid tissue. J. Exp. Med. 204, 723–734 (2007).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10

    GeurtsvanKessel, C.H. et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J. Exp. Med. 206, 2339–2349 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  11. 11

    Chvatchko, Y., Kosco-Vilbois, M.H., Herren, S., Lefort, J. & Bonnefoy, J.Y. Germinal center formation and local immunoglobulin E (IgE) production in the lung after an airway antigenic challenge. J. Exp. Med. 184, 2353–2360 (1996).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. 12

    Aloisi, F. & Pujol-Borrell, R. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. 6, 205–217 (2006).

    CAS  PubMed  Article  Google Scholar 

  13. 13

    Tschernig, T. & Pabst, R. Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases. Pathobiology 68, 1–8 (2000).

    CAS  PubMed  Article  Google Scholar 

  14. 14

    Pabst, R. & Gehrke, I. Is the bronchus-associated lymphoid tissue (BALT) an integral structure of the lung in normal mammals, including humans? Am. J. Respir. Cell Mol. Biol. 3, 131–135 (1990).

    CAS  PubMed  Article  Google Scholar 

  15. 15

    Fagarasan, S., Muramatsu, M., Suzuki, K., Nagaoka, H., Hiai, H. & Honjo, T. Critical roles of activation-induced cytidine deaminase in the homeostasis of gut flora. Science 298, 1424–1427 (2002).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  16. 16

    Drayton, D.L., Liao, S., Mounzer, R.H. & Ruddle, N.H. Lymphoid organ development: from ontogeny to neogenesis. Nat. Immunol. 7, 344–353 (2006).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  17. 17

    Carragher, D.M., Rangel-Moreno, J. & Randall, T.D. Ectopic lymphoid tissues and local immunity. Semin. Immunol. 20, 26–42 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18

    Salomonsson, S., Larsson, P., Tengner, P., Mellquist, E., Hjelmstrom, P. & Wahren-Herlenius, M. Expression of the B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjogren's syndrome. Scand. J. Immunol. 55, 336–342 (2002).

    CAS  PubMed  Article  Google Scholar 

  19. 19

    Rangel-Moreno, J., Hartson, L., Navarro, C., Gaxiola, M., Selman, M. & Randall, T.D. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J. Clin. Invest. 116, 3183–3194 (2006).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  20. 20

    Marchal-Somme, J. et al. Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis. J. Immunol. 176, 5735–5739 (2006).

    CAS  PubMed  Article  Google Scholar 

  21. 21

    Gregorio, A. et al. Lymphoid neogenesis in juvenile idiopathic arthritis correlates with ANA positivity and plasma cells infiltration. Rheumatology (Oxford) 46, 308–313 (2007).

    CAS  Article  Google Scholar 

  22. 22

    Weyand, C.M. & Goronzy, J.J. Ectopic germinal center formation in rheumatoid synovitis. Ann. NY Acad. Sci. 987, 140–149 (2003).

    CAS  PubMed  Article  Google Scholar 

  23. 23

    Sato, A., Hayakawa, H., Uchiyama, H. & Chida, K. Cellular distribution of bronchus-associated lymphoid tissue in rheumatoid arthritis. Am. J. Respir. Crit. Care Med. 154 (6 Pt 1), 1903–1907 (1996).

    CAS  PubMed  Article  Google Scholar 

  24. 24

    Elliot, J.G., Jensen, C.M., Mutavdzic, S., Lamb, J.P., Carroll, N.G. & James, A.L. Aggregations of lymphoid cells in the airways of nonsmokers, smokers, and subjects with asthma. Am. J. Respir. Crit. Care Med. 169, 712–718 (2004).

    PubMed  Article  Google Scholar 

  25. 25

    Lee, J.J. et al. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J. Exp. Med. 185, 2143–2156 (1997).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26

    Richmond, I., Pritchard, G.E., Ashcroft, T., Avery, A., Corris, P.A. & Walters, E.H. Bronchus associated lymphoid tissue (BALT) in human lung: its distribution in smokers and non-smokers. Thorax 48, 1130–1134 (1993).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  27. 27

    van der Strate, B.W. et al. Cigarette smoke-induced emphysema: a role for the B cell? Am. J. Respir. Crit. Care Med. 173, 751–758 (2006).

    CAS  PubMed  Article  Google Scholar 

  28. 28

    Hogg, J.C. et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl. J. Med. 350, 2645–2653 (2004).

    CAS  PubMed  Article  Google Scholar 

  29. 29

    Moyron-Quiroz, J.E. et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat. Med. 10, 927–934 (2004).

    CAS  PubMed  Article  Google Scholar 

  30. 30

    Halle, S. et al. Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J. Exp. Med. 206, 2593–2601 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. 31

    Luhrmann, A., Tschernig, T. & Pabst, R. Stimulation of bronchus-associated lymphoid tissue in rats by repeated inhalation of aerosolized lipopeptide MALP-2. Pathobiology 70, 266–269 (2002).

    PubMed  Article  CAS  Google Scholar 

  32. 32

    Banfi, A. et al. Development of bronchus-associated lymphoid tissue hyperplasia following lipopolysaccharide-induced lung inflammation in rats. Exp. Lung Res. 35, 186–197 (2009).

    CAS  PubMed  Article  Google Scholar 

  33. 33

    Lorenz, R.G., Chaplin, D.D., McDonald, K.G., McDonough, J.S. & Newberry, R.D. Isolated lymphoid follicle formation is inducible and dependent upon lymphotoxin-sufficient B lymphocytes, lymphotoxin beta receptor, and TNF receptor I function. J. Immunol. 170, 5475–5482 (2003).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. 34

    Yoshida, H. et al. Expression of alpha(4)beta(7) integrin defines a distinct pathway of lymphoid progenitors committed to T cells, fetal intestinal lymphotoxin producer, NK, and dendritic cells. J. Immunol. 167, 2511–2521 (2001).

    CAS  PubMed  Article  Google Scholar 

  35. 35

    Tsuji, M. et al. Requirement for lymphoid tissue-inducer cells in isolated follicle formation and T cell-independent immunoglobulin A generation in the gut. Immunity 29, 261–271 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  36. 36

    Yokota, Y. et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 397, 702–706 (1999).

    CAS  PubMed  Article  Google Scholar 

  37. 37

    Eberl, G. & Littman, D.R. The role of the nuclear hormone receptor RORgammat in the development of lymph nodes and Peyer's patches. Immunol. Rev. 195, 81–90 (2003).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  38. 38

    Fukuyama, S. et al. Initiation of NALT organogenesis is independent of the IL-7R, LT[beta]R, and NIK signaling pathways but requires the Id2 gene and CD3-CD4+CD45+ cells. Immunity 17, 31–40 (2002).

    CAS  PubMed  Article  Google Scholar 

  39. 39

    Marinkovic, T. et al. Interaction of mature CD3+CD4+ T cells with dendritic cells triggers the development of tertiary lymphoid structures in the thyroid. J. Clin. Invest. 116, 2622–2632 (2006).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. 40

    Mebius, R.E. Organogenesis of lymphoid tissues. Nat. Rev. Immunol. 3, 292–303 (2003).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. 41

    Ansel, K.M. et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406, 309–314 (2000).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. 42

    Lee, M.K. IV et al. T-reg mediated suppression of the allograft response in the draining lymph node. Transplantation 81, 1063–1066 (2006).

    PubMed  Article  Google Scholar 

  43. 43

    Rangel-Moreno, J., Moyron-Quiroz, J.E., Hartson, L., Kusser, K. & Randall, T.D. Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. Proc. Natl. Acad. Sci. USA 104, 10577–10582 (2007).

    CAS  PubMed  Article  Google Scholar 

  44. 44

    Scheu, S., Alferink, J., Potzel, T., Barchet, W., Kalinke, U. & Pfeffer, K. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J. Exp. Med. 195, 1613–1624 (2002).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45

    Nishikawa, S., Honda, K., Vieira, P. & Yoshida, H. Organogenesis of peripheral lymphoid organs. Immunol. Rev. 195, 72–80 (2003).

    CAS  PubMed  Article  Google Scholar 

  46. 46

    Drayton, D.L., Ying, X., Lee, J., Lesslauer, W. & Ruddle, N.H. Ectopic LT alpha beta directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase. J. Exp. Med. 197, 1153–1163 (2003).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  47. 47

    Ngo, V.N. et al. Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J. Exp. Med. 189, 403–412 (1999).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. 48

    Ying, X., Chan, K., Shenoy, P., Hill, M. & Ruddle, N.H. Lymphotoxin plays a crucial role in the development and function of nasal-associated lymphoid tissue through regulation of chemokines and peripheral node addressin. Am. J. Pathol. 166, 135–146 (2005).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. 49

    Xu, B. et al. Lymphocyte homing to bronchus-associated lymphoid tissue (BALT) is mediated by L-selectin/PNAd, alpha4beta1 integrin/VCAM-1, and LFA-1 adhesion pathways. J. Exp. Med. 197, 1255–1267 (2003).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  50. 50

    Kawamata, N. et al. Expression of endothelia and lymphocyte adhesion molecules in bronchus-associated lymphoid tissue (BALT) in adult human lung. Respir. Res. 10, 97 (2009).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  51. 51

    Takemura, S. et al. Lymphoid neogenesis in rheumatoid synovitis. J. Immunol. 167, 1072–1080 (2001).

    CAS  PubMed  Article  Google Scholar 

  52. 52

    Manzo, A. et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur. J. Immunol. 35, 1347–1359 (2005).

    CAS  PubMed  Article  Google Scholar 

  53. 53

    De Togni, P. et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264, 703–707 (1994).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  54. 54

    Banks, T.A. et al. Lymphotoxin-alpha-deficient mice. Effects on secondary lymphoid organ development and humoral immune responsiveness. J. Immunol. 155, 1685–1693 (1995).

    CAS  PubMed  Google Scholar 

  55. 55

    Vuillemenot, B.R., Rodriguez, J.F. & Hoyle, G.W. Lymphoid tissue and emphysema in the lungs of transgenic mice inducibly expressing tumor necrosis factor-{alpha}. Am. J. Respir. Cell Mol. Biol. 30, 438–448 (2004).

    CAS  PubMed  Article  Google Scholar 

  56. 56

    Goya, S. et al. Sustained interleukin-6 signalling leads to the development of lymphoid organ-like structures in the lung. J. Pathol. 200, 82–87 (2003).

    CAS  PubMed  Article  Google Scholar 

  57. 57

    Legler, D.F., Loetscher, M., Roos, R.S., Clark-Lewis, I., Baggiolini, M. & Moser, B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J. Exp. Med. 187, 655–660 (1998).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58

    Luther, S.A., Lopez, T., Bai, W., Hanahan, D. & Cyster, J.G. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 12, 471–481 (2000).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  59. 59

    Luther, S.A., Ansel, K.M. & Cyster, J.G. Overlapping roles of CXCL13, interleukin 7 receptor alpha, and CCR7 ligands in lymph node development. J. Exp. Med. 197, 1191–1198 (2003).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  60. 60

    Luther, S.A., Tang, H.L., Hyman, P.L., Farr, A.G. & Cyster, J.G. Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the ELC gene in the plt/plt mouse. Proc. Natl Acad. Sci. USA 97, 12694–12699 (2000).

    CAS  PubMed  Article  Google Scholar 

  61. 61

    Marchal-Somme, J. et al. Dendritic cells accumulate in human fibrotic interstitial lung disease. Am. J. Respir. Crit. Care Med. 176, 1007–1014 (2007).

    PubMed  Article  Google Scholar 

  62. 62

    Fukuyama, S. et al. Cutting edge: uniqueness of lymphoid chemokine requirement for the initiation and maturation of nasopharynx-associated lymphoid tissue organogenesis. J. Immunol. 177, 4276–4280 (2006).

    CAS  PubMed  Article  Google Scholar 

  63. 63

    Gribar, S.C., Anand, R.J., Sodhi, C.P. & Hackam, D.J. The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation. J. Leukoc. Biol. 83, 493–498 (2008).

    CAS  PubMed  Article  Google Scholar 

  64. 64

    Sha, Q., Truong-Tran, A.Q., Plitt, J.R., Beck, L.A. & Schleimer, R.P. Activation of airway epithelial cells by toll-like receptor agonists. Am. J. Respir. Cell Mol. Biol. 31, 358–364 (2004).

    PubMed  Article  CAS  Google Scholar 

  65. 65

    Emery, J.L. & Dinsdale, F. The postnatal development of lymphoreticular aggregates and lymph nodes in infants’ lungs. J. Clin. Pathol. 26, 539–545 (1973).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  66. 66

    Tschernig, T., Kleemann, W.J. & Pabst, R. Bronchus-associated lymphoid tissue (BALT) in the lungs of children who had died from sudden infant death syndrome and other causes. Thorax 50, 658–660 (1995).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  67. 67

    Gould, S.J. & Isaacson, P.G. Bronchus-associated lymphoid tissue (BALT) in human fetal and infant lung. J. Pathol. 169, 229–234 (1993).

    CAS  PubMed  Article  Google Scholar 

  68. 68

    Delventhal, S., Hensel, A., Petzoldt, K. & Pabst, R. Effects of microbial stimulation on the number, size and activity of bronchus-associated lymphoid tissue (BALT) structures in the pig. Int. J. Exp. Pathol. 73, 351–357 (1992).

    CAS  PubMed  PubMed Central  Google Scholar 

  69. 69

    Meuwissen, H.J. & Hussain, M. Bronchus-associated lymphoid tissue in human lung: correlation of hyperplasia with chronic pulmonary disease. Clin. Immunol. Immunopathol. 23, 548–561 (1982).

    CAS  PubMed  Article  Google Scholar 

  70. 70

    Cupedo, T., Jansen, W., Kraal, G. & Mebius, R.E. Induction of secondary and tertiary lymphoid structures in the skin. Immunity 21, 655–667 (2004).

    CAS  PubMed  Article  Google Scholar 

  71. 71

    Phipps, S., Hansbro, N., Lam, C.E., Foo, S.Y., Matthaei, K.I. & Foster, P.S. Allergic sensitization is enhanced in early life through toll-like receptor 7 activation. Clin. Exp. Allergy 39, 1920–1928 (2009).

    CAS  PubMed  Article  Google Scholar 

  72. 72

    Luhrmann, A., Grote, K., Stephan, M., Tschernig, T. & Pabst, R. Local pulmonary immune stimulation by the Toll-like receptor 2 and 6 ligand MALP-2 in rats is age dependent. Immunol. Lett. 108, 167–173 (2007).

    PubMed  Article  CAS  Google Scholar 

  73. 73

    Pabst, R., Durak, D., Roos, A., Luhrmann, A. & Tschernig, T. TLR2/6 stimulation of the rat lung: effects on lymphocyte subsets, natural killer cells and dendritic cells in different parts of the air-conducting compartments and at different ages. Immunology 126, 132–139 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  74. 74

    Moyron-Quiroz, J.E. et al. Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity 25, 643–654 (2006).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  75. 75

    Steinman, R.M. Dendritic cells: understanding immunogenicity. Eur. J. Immunol. 37 (Suppl 1), S53–S60 (2007).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  76. 76

    Beaty, S.R., Rose, C.E. Jr & Sung, S.S. Diverse and potent chemokine production by lung CD11bhigh dendritic cells in homeostasis and in allergic lung inflammation. J. Immunol. 178, 1882–1895 (2007).

    CAS  PubMed  Article  Google Scholar 

  77. 77

    Van Pottelberge, G.R. et al. Plasmacytoid dendritic cells in pulmonary lymphoid follicles of patients with COPD. Eur. Respir. J., published online 29 March 2010 (doi:10.1183/09031936.00140409).

    CAS  PubMed  Article  Google Scholar 

  78. 78

    Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151–1164 (1995).

    CAS  PubMed  Google Scholar 

  79. 79

    Cederbom, L., Hall, H. & Ivars, F. CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur. J. Immunol. 30, 1538–1543 (2000).

    CAS  PubMed  Article  Google Scholar 

  80. 80

    Misra, N., Bayry, J., Lacroix-Desmazes, S., Kazatchkine, M.D. & Kaveri, S.V. Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J. Immunol. 172, 4676–4680 (2004).

    CAS  PubMed  Article  Google Scholar 

  81. 81

    Serra, P. et al. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. Immunity 19, 877–889 (2003).

    CAS  PubMed  Article  Google Scholar 

  82. 82

    Thornton, A.M. & Shevach, E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188, 287–296 (1998).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  83. 83

    Nakamura, K., Kitani, A. & Strober, W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 194, 629–644 (2001).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  84. 84

    Ueha, S. et al. CCR7 mediates the migration of Foxp3+ regulatory T cells to the paracortical areas of peripheral lymph nodes through high endothelial venules. J. Leukoc. Biol. 82, 1230–1238 (2007).

    CAS  PubMed  Article  Google Scholar 

  85. 85

    Tirouvanziam, R. et al. Ex vivo development of functional human lymph node and bronchus-associated lymphoid tissue. Blood 99, 2483–2489 (2002).

    CAS  PubMed  Article  Google Scholar 

  86. 86

    Heier, I. et al. Bronchial response pattern of antigen presenting cells and regulatory T cells in children less than 2 years of age. Thorax 63, 703–709 (2008).

    CAS  PubMed  Article  Google Scholar 

  87. 87

    Tsuji, M. et al. Preferential generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer's patches. Science 323, 1488–1492 (2009).

    CAS  PubMed  Article  Google Scholar 

  88. 88

    McDermott, M.R. & Bienenstock, J. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J. Immunol. 122, 1892–1898 (1979).

    CAS  PubMed  PubMed Central  Google Scholar 

  89. 89

    Rudzik, R., Clancy, R.L., Perey, D.Y., Day, R.P. & Bienenstock, J. Repopulation with IgA-containing cells of bronchial and intestinal lamina propria after transfer of homologous Peyer's patch and bronchial lymphocytes. J. Immunol. 114, 1599–1604 (1975).

    CAS  PubMed  Google Scholar 

  90. 90

    Kocks, J.R. et al. Chemokine receptor CCR7 contributes to a rapid and efficient clearance of lytic murine gamma-herpes virus 68 from the lung, whereas bronchus-associated lymphoid tissue harbors virus during latency. J. Immunol. 182, 6861–6869 (2009).

    CAS  PubMed  Article  Google Scholar 

  91. 91

    Wiley, J.A. et al. Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses. PLoS One 4, e7142 (2009).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  92. 92

    Norton, E.B., Clements, J.D., Voss, T.G. & Cardenas-Freytag, L. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J. Virol. 84, 2983–2995 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references

Acknowledgements

SYF is supported by a scholarship from the Priority Research Centre for Asthma and Respiratory Diseases, University of Newcastle. SP is supported by funding from the NHMRC of Australia.

Author information

Affiliations

Authors

Corresponding author

Correspondence to S Phipps.

Additional information

DISCLOSURE

The authors declared no conflict of interest.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Foo, S., Phipps, S. Regulation of inducible BALT formation and contribution to immunity and pathology. Mucosal Immunol 3, 537–544 (2010). https://doi.org/10.1038/mi.2010.52

Download citation

Further reading

Search

Quick links